Glenmark launches Clindamycin Phosphate Foam
The new product targets a market worth $5.8 million
Glenmark Pharmaceuticals,USA (Glenmark), has launched Clindamycin Phosphate Foam, 1 per cent. The product is bioequivalent and therapeutically equivalent to Mylan Pharmaceuticals Inc.’s reference listed drug, Evoclin Foam, 1 per cent.
According to IQVIA sales data for the 12-month period ending December 2024, the market for Evoclin Foam, 1 per cent achieved annual sales of approximately $5.8 million.